




Contents lists available at ScienceDirect

Gynecologic Oncology

journal homepage: www.elsevier.com/locate/ygyno

Characterization of *TP53* mutations in Pap test DNA of women with and without serous ovarian carcinoma

Jeffrey D. Krimmel-Morrison^{a,b}, Talayah S. Ghezelayagh^{b,c}, Shenyi Lian^{b,1}, Yuezheng Zhang^b, Jeanne Fredrickson^b, Daniela Nachmanson^{b,2}, Kathryn T. Baker^{b,3}, Marc R. Radke^c, Enna Hun^c, Barbara M. Norquist^c, Mary J. Emond^d, Elizabeth M. Swisher^c, Rosa Ana Risques^{b,*}

^a Department of Medicine, University of Washington, Seattle, WA 98195, USA

^b Department of Pathology, University of Washington, Seattle, WA 98195, USA

^c Department of Obstetrics and Gynecology, University of Washington, Seattle, WA 98195, USA

^d Department of Statistics, University of Washington, Seattle, WA 98195, USA

HIGHLIGHTS

- Tumor-derived *TP53* mutations were detected in Pap tests in about one-third of women with ovarian cancer.
- Low-frequency *TP53* mutations were present in Pap tests in all women with and without ovarian cancer.
- Pap test *TP53* mutations resemble *TP53* mutations found in cancer.
- Cancer-like Pap test mutations are more common in women with ovarian cancer.

ARTICLE INFO

Article history:

Received 1 September 2019

Received in revised form 28 November 2019

Accepted 30 November 2019

Available online 12 December 2019

Keywords:

Epithelial ovarian cancer

Deep sequencing

Papanicolaou test

Biomarker

TP53 gene

ABSTRACT

Objective. Pap tests hold promise as a molecular diagnostic for serous ovarian cancer, but previous studies reported limited sensitivity. Furthermore, the presence of somatic mutations in normal tissue is increasingly recognized as a challenge to the specificity of mutation-based cancer diagnostics. We applied an ultra-deep sequencing method with the goal of improving sensitivity and characterizing the landscape of low-frequency somatic *TP53* mutations in Pap tests.

Methods. We used CRISPR-DS to deeply sequence (mean Duplex depth ~3000×) the *TP53* gene in 30 Pap tests from 21 women without cancer and 9 women with serous ovarian carcinoma with known *TP53* driver mutations. Mutations were annotated and compared to those in the *TP53* cancer database.

Results. The tumor-derived mutation was identified in 3 of 8 Pap tests from women with ovarian cancer and intact tubes. In addition, 221 low-frequency (≤ 0.001) exonic *TP53* mutations were identified in Pap tests from women with ovarian cancer (94 mutations) and without ovarian cancer (127 mutations). Many of these mutations resembled *TP53* mutations found in cancer: they impaired protein activity, were predicted to be pathogenic, and clustered in exons 5 to 8 and hotspot codons. Cancer-like mutations were identified in all women but at higher frequency in women with ovarian cancer.

Conclusions. Pap tests have low sensitivity for ovarian cancer detection and carry abundant low-frequency *TP53* mutations. These mutations are more frequently pathogenic in women with ovarian cancer. Determining whether low-frequency *TP53* mutations in normal gynecologic tissues are associated with an increased cancer risk warrants further study.

© 2019 Elsevier Inc. All rights reserved.

* Corresponding author at: Dept. of Pathology, University of Washington, Box 357470, 1959 NE Pacific Ave., Seattle, WA 98195-7705, USA.

E-mail address: risques@uw.edu (R.A. Risques).

¹ Present address: Key laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, PR, China.

² Present address: Bioinformatics and Systems Biology Graduate Program, University of California San Diego, La Jolla, CA, USA.

³ Present address: Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.

1. Introduction

High-grade serous ovarian, fallopian tube, and peritoneal carcinoma (HGSC) is the most common subtype of ovarian cancer [1]. Most women with HGSC present in advanced stage, which renders a dismal overall 5-year survival of approximately 30% in contrast to 90% for early stage ovarian cancers [2]. The development of screening methods to detect ovarian cancer has been a principal but elusive research goal for decades. Since the advent of Next Generation Sequencing (NGS), the “liquid biopsy” approach (the detection of tumor-derived DNA in minimally-invasive clinical samples) has emerged with promise to revolutionize cancer diagnostics [3].

Pap tests are particularly attractive as a potential tool for ovarian cancer screening because they are minimally-invasive and already an established component of women’s preventive healthcare [4]. Pap tests consist primarily of cervical epithelial cells, but are known to contain small populations of cells from proximal components of the female reproductive tract including endometrial, fallopian tube, and ovarian epithelium [5]. In two promising initial studies, Kinde et al. [6] and Wang et al. [7] detected ovarian tumor-derived DNA in 41% and 29% of associated Pap tests, respectively, using Safe-SeqS, a high-accuracy deep sequencing method [8]. While Safe-SeqS improves the mutation detection threshold of NGS by two orders of magnitude [9], it may still be insufficient for this clinical application. We hypothesized that the use of a more accurate sequencing technique could improve sensitivity and better define the utility of Pap tests to detect ovarian cancer.

Duplex Sequencing (DS) is an ultra-accurate NGS method estimated to have an error rate two orders of magnitude less than Safe-SeqS [9–11]. We previously demonstrated that DS can identify a single tumor mutation among ~24,000 normal genomes [12]. Here we proposed to utilize the high sensitivity of DS for the detection of tumor-derived DNA in Pap tests. We targeted *TP53* exclusively because mutations in this gene are highly prevalent (>96%) in both HGSC [13–15] and high grade intraepithelial tubal neoplasia [16].

In addition to determining the sensitivity of Pap tests for HGSC detection, we also aimed to better define the specificity of this approach by analyzing Pap tests from women without malignant disease. Somatic mutations in cancer “driver” genes (such as *TP53*) were long presumed to be specific for malignancy, but mounting evidence indicates that these mutations are common in non-cancerous tissues, where they accumulate with age [17–19]. These findings challenge the concept of the “liquid biopsy”, which must be interpreted in context of the mutational background of the non-malignant tissue that is sampled [20]. Here we characterize the landscape of somatic *TP53* mutations in Pap tests from women without cancer and compare with that of women with HGSC in order to better understand the potential role of Pap tests as a diagnostic tool for HGSC.

2. Methods

2.1. Patients and samples

The study included a cohort of 30 women with or without HGSC who underwent gynecological surgery at the University of Washington due to pelvic masses suspicious for malignancy or prophylactic salpingo-oophorectomy due to inherited mutations in *BRCA1* or *BRCA2* (*BRCA* mutation carriers). Women were enrolled at diagnosis under an IRB-approved protocol at the University of Washington and consented to tissue collection including blood, tumor, and a pre-operative Pap test. Pap tests were collected in the OR prior to the start of surgery with an endocervical cytobrush (Thinprep, Hologic, MA, USA) according to manufacturer’s protocol. Samples were centrifuged at 2700 rpm for 15 min and cell pellets were stored in 1.7 mL of media at –80 °C at the University of Washington Gynecologic Oncology Tissue Bank. Final patient selection was based on availability of sufficient DNA samples given the pilot study design. Clinico-pathological information was recorded for

each patient (Table 1, Supplementary Table S1). None of the patients had prior salpingectomy, but four patients had prior tubal ligations. One of the patients was in the HGSC group and thus was excluded from sensitivity analyses. Tumors were surgically staged according to the International Federation of Obstetrics and Gynecology (FIGO) criteria. Sectioning and extensively examining the fimbriated end (SEE-FIM) was performed for all cases of cancer and all germline *BRCA* mutation carriers (in patients without cancer no gross or microscopic disease was detected). The BROCA sequencing panel was used to determine germline DNA mutations in *BRCA1*, *BRCA2* and other known ovarian cancer genes in all cancer patients [21]. In the benign group, only the patients with high-risk family history and/or known inherited *BRCA* mutations undergoing risk-reducing salpingo-oophorectomy were tested for germline mutations.

2.2. Pap test DNA extraction

Pap tests were centrifuged at 1000 g for 3 min and DNA was extracted from the cell pellet using the QIAamp DNA Mini kit (Qiagen, Valencia, CA, USA). The yield of Pap test DNA averaged 6.46 µg (range: 650 ng–14.5 µg). DNA was also extracted from fresh-frozen tumors (from areas of ≥60% neoplastic cellularity).

2.3. *TP53* mutation detection in cancers

TP53 mutations in primary tumors were determined by NGS as previously described [22].

2.3.1. CRISPR-DS

We used CRISPR-DS to sequence *TP53* as previously described [23]. CRISPR-DS incorporates CRISPR/Cas9 target enrichment prior to library preparation, which reduces the need for two rounds of hybridization capture while preserving the high accuracy of DS. 250 ng of genomic Pap test DNA was digested with CRISPR/Cas9 using guide RNAs designed to excise the coding region of *TP53* (exons 2–11) in fragments of ~500 bp (Supplementary Fig. S1). Then the excised fragments were recovered by size selection using AMPure XP Beads (Beckman Coulter, Brea, CA, USA) and processed for library preparation (Supplementary

Table 1
Clinico-pathological characteristics of patients.

	No. (%)		
	Total	Benign (N = 21)	High grade serous cancer (N = 9)
Median age (range)	54.5 (19–82)	51 (19–82)	65 (48–72)
Menopausal status			
Pre	10 (33.3%)	9 (42.9%)	1 (11.1%)
Post	20 (66.7%)	12 (57.1%)	8 (88.9%)
Mutation status			
None	18 (60.0%)	12 (57.1%)	6 (66.7%)
BRCA1	6 (20.0%)	3 (14.3%)	3 (33.3%)
BRCA2	6 (20.0%)	6 (28.6%)	
Histology			
No neoplasm	12 (40%)	12 (57.1%)	
Benign neoplasm*	9 (30%)	9 (42.9%)	
High grade serous cancer	9 (30%)		9 (100%)
Stage			
III			8 (88.9%)
IV			1 (11.1%)
Prior cancer diagnosis			
No	29 (96.7%)	21 (100%)	8 (88.9%)
Yes	1 (3.3%)		1 (11.1%)
Prior chemotherapy			
No	28 (93.3%)	21 (100%)	7 (77.8%)
Yes	2 (6.7%) [†]		2 (22.2%) [†]

* Benign neoplasms included serous cystadenoma, mucinous cystadenoma, serous cystadenofibroma, endometriosis, salpingitis, fibroma, cellular angiofibroma, and struma ovarii

[†] Received neoadjuvant chemotherapy for ovarian cancer

Methods). Sequencing data was analyzed using the CRISPR-DS pipeline available at <https://github.com/risqueslab/CRISPR-DS> [23]. Raw reads were grouped to produce single-strand consensus sequences for each DNA strand. Then complementary strands of the same DNA molecule were compared to produce Duplex reads (Supplementary Fig. S1), which were aligned to the human genome reference hg19 (GRCH37) and processed to extract mutational information.

2.4. Mutational analysis

For each individual mutation, mutant allele frequency (MAF) was calculated as number of reads with the mutation divided by the total Duplex reads sequenced at that position. For each sample, *TP53* mutation frequency was calculated as the number of unique coding or splicing mutations in *TP53* (excluding the tumor mutation) divided by the total number of Duplex nucleotides sequenced in exons (Supplementary Table S2). For each sample, Duplex depth was calculated as the number of Duplex nucleotides sequenced in exons divided by the size of the *TP53* coding region. The mean Duplex depth for the 30 Pap tests was 3068× (range: 811×–7440×) (Supplementary Table S2).

2.5. Characterization of *TP53* mutations using Seshat

All *TP53* variants identified in exons and splice-sites in Pap tests from women with and without HGSC ($n = 224$) were submitted to Seshat (<https://p53.fr/TP53-database/seshat>), a web service that performs *TP53* mutation annotation and characterization using data derived from the UMD *TP53* database [24] (Supplementary Methods, Supplementary Table S3). Mutations were analyzed based on mutation type (missense, nonsense, splice, insertion or deletion, synonymous), mutation spectrum (6 possible nucleotide substitutions), location in exons 5 to 8 (which encode the DNA binding domain), location in mutational hotspot codons (9 most commonly mutated codons in the UMD *TP53* database for all cancers: 175, 179, 213, 220, 245, 248, 249, 273, 282), reported frequency of the mutation in the cancer database, functional activity, and predicted pathogenicity. For each patient, we calculated the mutation frequency in each category by dividing the number of mutations by the total number of Duplex nucleotides sequenced in exons in order to compensate for differences in sequencing depth between patients.

2.6. Comparison with all possible *TP53* nucleotide substitutions

A list of all possible single nucleotide substitutions in the *TP53* coding region ($n = 3546$) was generated in silico and submitted to Seshat to determine the distribution of mutations in the following categories: frequency in the cancer database, protein activity, predicted pathogenicity, location in exons 5–8, and location in hotspots [18]. The values obtained were used for comparison with *TP53* Pap test mutations identified in women with and without HGSC.

2.7. Comparison with *TP53* cancer database mutations

From the UMD *TP53* database (April 2017 version), we identified 71,051 mutations reported within human tumors (mutations from cell lines, normal and premalignant tissue were excluded). Then we determined the distribution of mutations in the following categories: frequency in the cancer database, protein activity, predicted pathogenicity, location in exons 5–8, and location in hotspots [18]. These values were used to compare *TP53* cancer mutations with *TP53* Pap test mutations identified in women with and without HGSC.

2.8. Statistical analysis

Correlations were tested with Spearman's rank test or with quasibinomial tests in order to explicitly account for the different

sequencing depth across individuals (lower depth results in a lower probability of finding mutations). Comparison of means across categories of mutations was performed by *t*-test. Comparison of the distribution of mutational features in Pap tests vs. all possible *TP53* mutations was performed with chi-square. All tests were two-sided at an alpha level (type 1 error rate) of 0.05. Statistical analyses were performed with STATA and R.

3. Results

3.1. Low-frequency somatic *TP53* mutations are detected in Pap tests from all patients with and without HGSC

The cohort included nine patients with HGSC (30%) and 21 patients with benign pathology (70%). Clinico-pathological information is summarized in Table 1. All patients with HGSC had stage III or IV disease. Three patients with HGSC (33%) and nine patients with benign pathology (43%) carried a germline *BRCA1* or *BRCA2* mutation. A single clonal *TP53* mutation was found in all tumors (Supplementary Table S1). No additional clonal or subclonal *TP53* mutations were found in any of the primary tumors using conventional NGS.

We performed ultra-deep sequencing of *TP53* (mean depth = 3068×) in Pap tests from all 30 women. A total of 571 *TP53* variants were identified, 256 of which were located in exons or splicing sites and 315 were located in introns. 137 variants were germline polymorphisms (32 exonic and 105 intronic) as demonstrated by MAF around 0.5 and 1.0 and Seshat database confirmation. After removing polymorphisms and intronic mutations, 224 exonic mutations (including coding and splicing, Supplementary Table S3) remained for analysis. All these mutations were present at very low-frequency (MAF < 0.01) and were identified in patients with and without HGSC (Fig. 1).

Of the 224 exonic mutations, only 3 were tumor-derived mutations (i.e. matched the clonal driver *TP53* mutation present in the tumor). This resulted in a sensitivity of 37.8% for the detection of HGSC mutations in Pap test DNA (3 positive patients out of 8 patients with HGSC and intact fallopian tubes, Fig. 1). The MAF of the tumor-derived mutations was 0.00135, 0.00029, and 0.00671 for patients 22, 26, and 27, respectively. All 3 Pap tests with tumor-derived mutations contained additional low-frequency *TP53* mutations, although in 2 of these 3 cases (patients 22 and 27), the tumor-derived mutant allele was the most abundant mutation. All patients carried low-frequency *TP53* mutations, including the four patients that had undergone prior tubal ligations. In total, we identified 94 *TP53* mutations in ovarian cancer patients and 127 *TP53* mutations in benign patients. The mean number of mutations per sample was 7.4 (range: 1–26, Supplementary Table S2).

The number of mutations was correlated with the Duplex depth for each sample ($p=0.0007$ by Spearman's rank correlation test, Supplementary Fig. S2). To account for that association, samples were compared based on mutation frequency, which is calculated as the number of mutations divided by the total number of nucleotides sequenced. *TP53* mutation frequency was highly variable across patients and it was not significantly associated with age in benign or cancer patients when tested using Spearman's rank test (Supplementary Fig. S3, $p=0.51$ and $p=0.41$ respectively). However, because lower sequencing depth results in a lower probability to find mutations, we also used a quasibinomial model that considered different sequencing depth across individuals. The quasibinomial model revealed near-significant association between *TP53* mutation frequency and age in patients without cancer but not in patients with cancer (Supplementary Fig. S3, $p=0.06$ and $p=0.42$ respectively).

3.2. Cancer-like low-frequency *TP53* mutations are more frequent in women with ovarian cancer than in women without cancer

We next performed a detailed characterization of the *TP53* mutations identified in Pap tests. Pap tests from all patients both with and




Fig. 1. *TP53* mutations identified in Pap tests. A. Women with HGSC. B. Women without cancer. Each bar represents a *TP53* mutation. For each patient, mutations are sorted by descending Mutant Allele Frequency (MAF). Note that all mutations have MAF < 0.01 and most mutations have MAF < 0.001. The three mutations that correspond to matching primary tumor mutations are indicated in fuchsia. Patient ID is indicated in the X-axis. The four patients with prior tubal ligations are indicated with an asterisk.

without cancer contained non-synonymous mutations (Fig. 2A) and mutations with functional consequences (Fig. 2B–D). Overall, most mutations observed in the Pap tests were likely to have functional effects: 81.5% were non-synonymous, 68.3% resulted in an inactive or partially active protein in vitro, and 62.4% were predicted to be “possibly” or “likely” pathogenic. Consistent with this pathogenic role, 43% of all low-frequency *TP53* mutations identified in Pap tests were reported to be very frequent or frequent in the UMD cancer database, supporting the cancer-like nature of these mutations.

While cancer-like mutations were present in Pap tests from all patients, they appeared to be more abundant in cancer patients. When mutations were grouped according to their presence in the UMD *TP53* cancer database, we observed that mutations commonly found in cancers were approximately 3× more abundant in Pap tests from women with HGSC than in Pap tests from women without cancer (Fig. 3A, $p = 8 \times 10^{-4}$). Remarkably, the frequency of mutations infrequent in cancer was similar in both groups. A similar pattern emerged with mutation effect on protein activity and predicted pathogenicity (Fig. 3B and C). *TP53* mutations that inactivate the protein and are predicted to be pathogenic were approximately 2.7× and 2.9× more frequent,

respectively, in Pap tests from women with HGSC than in women without cancer (Fig. 3B, $p=0.004$ and Fig. 3C, $p = 9 \times 10^{-4}$). Conversely, there was no difference in the mutation frequency of any of the other categories of activity or pathogenicity between both groups of women. In summary, Pap tests from patients with ovarian cancer bear a higher abundance of low-frequency mutations with the most cancer-like characteristics: commonly reported in cancers, inactivating the protein, and likely pathogenic by computational prediction. A sensitivity analysis was performed for the purpose of excluding that the difference in mutation pattern observed could have been a product of the different proportion of germline *BRCA* mutation carriers in each group. When *BRCA* mutation carriers were excluded from both HGSC and benign groups and the analysis was repeated, Pap tests from patients with ovarian cancer were still significantly more likely to carry *TP53* mutations that were commonly reported in tumors ($p=0.011$) and likely pathogenic ($p=0.018$) (Supplementary Fig. S4A and S4C).

Given the functional differences observed between *TP53* mutations in Pap tests from women with and without ovarian cancer, we sought to determine whether there was a difference in whether mutations affected gene locations with biological impact. Indeed, we observed that




Fig. 2. Distribution of *TP53* mutations identified in Pap tests from patients with and without HGSC based on (A) mutation type, (B) common appearance in the UMD cancer database, (C) impact on in vitro protein activity, and (D) predicted pathogenicity. Patient ID is indicated in the Y-axis and patients are sorted by ascending age within each group. For each patient, mutation frequency was calculated as the number of *TP53* mutations divided by the total number of Duplex nucleotides sequenced in the *TP53* coding region. Syn: synonymous. VUS: variant of unknown significance.




Fig. 3. Comparison of *TP53* mutation frequency in Pap tests from women with and without HGSC based on (A) common appearance in the UMD cancer database, (B) inactivation of protein activity, (C) predicted pathogenicity, (D) location in exons 5–8, and (E) location in hotspot codons. For each mutation category, the mean of mutation frequency for patients with and without HGSC was compared using *t*-tests (benign $n = 21$, cancer $n = 9$). Only significant *p*-values are displayed. Error bars represent standard error of the mean.

the frequency of *TP53* mutations located in exons 5–8 (which encode the protein DNA binding domain) and in hotspot codons (the 9 most commonly mutated codons in the UMD *TP53* database) was significantly higher in Pap tests from women with cancer than in those from women cancer-free ($p = 0.044$ and 0.001 , respectively, Fig. 3D and E). The association with hotspot codons remained statistically significant when *BRCA* mutation carriers were excluded (Supplementary Fig. S4E, $p = 0.027$).

The mutational spectrum of *TP53* mutations identified in Pap tests from women with and without HGSC was similar, with a predominance of C:G > T:A transitions consistent with mutational signatures in cancer associated with age [25] (Supplementary Fig. S5). These results indicate that while the underlying mechanism causing mutations might be similar in both groups, functional *TP53* mutations in women with cancer were more common, as reflected by an enrichment of cancer-like mutations and predominant location in exons 5–8 and hotspot codons.

3.3. *TP53* mutations in Pap tests are not random and resemble *TP53* mutations found in cancers

We next compared the features of *TP53* mutations in Paps with the features of random *TP53* mutations and with *TP53* mutations identified in human cancer (Fig. 4). To determine the features of random *TP53* mutations, we generated the full set of all possible *TP53* nucleotide substitutions by changing in silico each coding nucleotide to the other 3 possible bases. We then cataloged this list of mutations ($n = 3546$) according to 5 features extracted from Seshat analysis: common in cancer (Fig. 4A), protein activity (Fig. 4B), predicted pathogenicity (Fig. 4C), exons 5–8 location (Fig. 4D), and hotspot location (Fig. 4E). The same features were extracted for the full set of *TP53* mutations reported in the UMD cancer database (April 2017, $n = 71,051$). We observed that, for these 5 distinct features, *TP53* mutations in Pap tests differed from random mutations and gradually shifted towards the distribution seen with cancer mutations. This shift indicates that *TP53* mutations found in Pap DNA are enriched for pathogenic features, especially in women with HGSC. Accordingly, for these 5 features, the percentage of Pap

mutations positive for the feature was statistically significantly higher than the expectation from random mutations both in women with and without HGSC, but with highest significance in the former (Supplementary Fig. S6).

3.4. The Pap test frequency of *TP53* mutations commonly reported in the UMD cancer database discriminates patients with and without ovarian cancer

As seen in Fig. 3A, patients with HGSC have a higher frequency of mutations that have been commonly reported in the UMD *TP53* database. The frequency of common-in-cancer *TP53* mutations identified in Pap tests could thus potentially discriminate patients with and without HGSC. In this small study, a threshold of $>1 \times 10^{-6}$ mutations/bp yield a sensitivity of 78% and specificity of 90% (Fig. 5). Of note, the woman with HGSC and tubal ligation had a high frequency of *TP53* mutations common in cancer, indicating that these mutations are not necessarily related to exfoliation from distal fallopian tube epithelium. Because the age range was wider in the group of women without cancer than in the group of women with cancer, we also plotted the data including the regression by age, which was significant for women without cancer (Supplementary Fig. S7, Spearman's rank correlation $p = 0.008$). We then calculated the sensitivity and specificity for the subset of patients matched by age (range 45 to 75). Sensitivity remained at 78% and specificity increased to 92% because one woman without cancer but with high frequency of mutation was older than 75 years. Upon exclusion of *BRCA* mutation carriers, sensitivity was 71% and specificity was 100%.

4. Discussion

The objective of this study was to use ultra-deep sequencing to improve the sensitivity of the Pap test to detect HGSC and to characterize the landscape of low-frequency somatic *TP53* mutations and their potential impact on specificity. We detected the tumor-derived *TP53* mutation in 3 of 8 cancer patients with intact fallopian tubes (38%), a




Fig. 4. Comparison of *TP53* mutations identified in Pap tests from women with and without HGSC vs. random *TP53* mutations and *TP53* mutations in the cancer database. Mutations were compared based on (A) common appearance in cancers, (B) inactivation of protein activity, (C) predicted pathogenicity, (D) location in exons 5–8, and (E) location in hotspot codons. ‘Random mutations’ includes all possible mutations in the *TP53* coding region ($n = 3546$), benign Paps include 127 mutations, cancer Paps include 94 mutations, and cancer database includes all *TP53* mutations identified in human cancers in the April 2017 version of the UMD cancer database ($n = 71,051$).

sensitivity similar to prior reports [6,7] despite the fact that we used a sequencing method with higher resolution [9]. This result suggests that the limited sensitivity of the Pap test to detect HGSC mutations is likely due to the absence of neoplastic DNA in the sample and not technical resolution. The resolution of Duplex Sequencing, however, enabled the novel identification of abundant low-frequency *TP53* mutations in Pap tests from all women, with and without HGSC. A substantial proportion of these mutations was common in cancer, inactivated protein activity, and was predicted to be pathogenic by computational models. Interestingly, common *TP53* cancer mutations were more frequent in




Fig. 5. The frequency of Pap test *TP53* mutations commonly reported in cancer distinguishes women with and without HGSC. *TP53* mutation frequency included only mutations identified by Seshat as very frequent or frequent in the UMD cancer database. The four patients with prior tubal ligations are indicated with an asterisk.

Pap tests from women with ovarian cancer than in Pap tests from women without cancer, suggesting an increased presence of potentially pathogenic *TP53* mutated clones in association with HGSC. Thus, it is possible that the mutational burden of pathogenic *TP53* mutations could serve as a tool in risk assessment, but such an application would require further study with longitudinal follow-up.

The finding of functional low-frequency mutations in Pap tests is consistent with a growing body of literature demonstrating the presence of cancer-like somatic mutations in normal tissues [17]. These mutations were initially studied in blood, where clones with leukemia-associated driver gene mutations (including *TP53*) were found in otherwise healthy individuals [26–29]. Similar findings of abundant, positively-selected, age-associated, cancer gene mutations have also been reported in normal skin [30], esophagus [31,32], and several other human tissues [19]. Relevant to gynecology, our group has demonstrated pervasive, positively selected, low-frequency *TP53* mutations in peritoneal fluid [12], uterine lavage [18], and normal gynecological tissues [18], and others have demonstrated cancer driver mutations in both normal endometrium and endometriosis [33–35]. Collectively, these findings support the concept of somatic evolution within normal tissue [17], which has important implications for the development of cancer detection tests based on mutational analysis of liquid biopsies, including Pap tests [20]. Because even archetypal cancer “driver” mutations (e.g. in *TP53*) are not specific to cancer, caution must be taken when interpreting the results from such tests. We and others have targeted *TP53* because mutations in this gene are highly prevalent even in intraepithelial tubal

neoplasia [16]. However, our results suggest that the simple presence or absence of a *TP53* mutation at any mutant allele frequency threshold in a Pap test is unlikely to be a robust biomarker to distinguish women with and without HGSC or precursor lesions. Our study highlights that future “liquid biopsy” studies should approach this challenge of specificity through careful analysis of patients without cancer from the target population for screening.

We have demonstrated, in agreement with prior studies [6,7], that the Pap test has limited sensitivity for ovarian cancer detection when relying on NGS identification of tumor-derived *TP53* mutations. Because we used an extremely sensitive sequencing technology [9] and detected mutations at frequencies <0.001, we have demonstrated this limitation is probably not technical. Most likely, the limited sensitivity of Pap tests is due to the distance between the site of collection (cervical canal) and the fallopian tubes, which are the presumed site of origin for most serous ovarian cancers [16,36]. This hypothesis is supported by the fact that Tao brushes and uterine lavages, which sample the uterine cavity, both have higher sensitivity for the detection of ovarian cancer cells [7,37]. Uterine lavage has the highest sensitivity reported so far (80%) [18,37], which makes it the most promising option as a minimally invasive method for ovarian cancer detection.

The most novel and clinically relevant finding from this study is the increased frequency of *TP53* cancer-like mutations in Pap tests from women with ovarian cancer compared to cancer-free women. This finding is supported by five mutational features analyzed in the study: frequency in cancer, protein activity, predicted pathogenicity, location in exons 5–8, and location in hotspot codons. The excess of pathogenic mutations in women with ovarian cancer is unlikely to be due to ovarian cancer subclones since no subclonal mutations were identified in any of the primary cancers. In addition, the finding of abundant pathogenic mutations in a woman with HGSC but prior tubal ligation indicates that, in this case, mutated cells could not have derived from the shedding of synchronous pathogenic clones located in the distal fimbria. However, one possibility is for these clones to have disseminated early in carcinogenesis, seeding the lower gynecological tract prior to the ligation of the tubes. An alternative hypothesis is that *TP53* mutant clones present in Pap DNA are simply derived from cervical or endometrial epithelium and reflect more advanced somatic evolution in individuals prone to developing cancer. If the latter hypothesis is true, then other non-malignant tissues (especially those that may be sampled non-invasively such as blood or buccal mucosa) may also exhibit an excess of *TP53* cancer-like mutations in individuals with or at risk of cancer, enabling new venues for cancer biomarker development. Our analysis suggests that significant differences in *TP53* cancer-like mutations still exist while excluding *BRCA* mutation carriers and in age-matched individuals, but large, properly designed longitudinal studies are needed to validate these results and to determine their clinical utility.

In summary, our study adds further evidence that the sensitivity of the Pap test is likely insufficient for ovarian cancer detection even using highly-accurate and ultra-deep sequencing methods. In addition, the finding of low-frequency *TP53* mutations in Pap tests is yet another example of prevalent deleterious mutations in a non-cancerous biopsy. The fact that cancer-like *TP53* mutations are more common in women with ovarian cancer is of clinical interest because Pap tests might be utilized in a two-stage approach to ovarian cancer diagnosis [38] (e.g. in which Pap tests with high burden of cancer-like mutations could be an indication to follow up with other diagnostic assays). Beyond the clinical applications, our findings raise questions regarding the cell of origin of these ubiquitous *TP53* mutated subclones and the mechanisms that prevent them from malignant transformation. The answers to these questions will provide important insight into refining our understanding of carcinogenesis and will reveal targets for future diagnostics and therapeutics.

Author contribution

JDK, EMS, and RAR designed the study; MRR, EH, BMN, and EMS procured the samples; JDK, SL, YZ, and JF processed the samples; JDK, TSG, DN, KTB, and RAR contributed to data analysis and visualization; TSG, MJE, and RAR performed statistical analyses; BMN and EMS contributed expertise and invaluable critical discussion; JDK, TSG, and RAR wrote the article.

Data and materials availability

Data deposition: Sequencing data from this Paper have been deposited online at <https://www.ncbi.nlm.nih.gov/bioproject/PRJNA529688> (BioProject ID: PRJNA529688).

Funding

NIH grant R01CA181308 to RAR; Mary Kay Foundation grant 045-15 to RAR; Rivkin Center for Ovarian Cancer grant 567612 to RAR.

Declaration of competing interest

RAR shares equity in NanoString Technologies Inc. and is the principal investigator on a NIH SBIR R44CA221426 subcontract research agreement with TwinStrand Biosciences Inc.

Acknowledgements

We thank Brendan Kohn and Scott Kennedy for data analysis and computational support. We deeply thank the patients who provided clinical samples, without which this research would not have been possible.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ygyno.2019.11.124>.

References

- [1] D.D. Bowtell, et al., Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer, *Nat. Rev. Cancer* 15 (11) (2015) 668–679.
- [2] R.L. Siegel, et al., Cancer statistics, 2019, *CA Cancer J. Clin.* 69 (1) (2019) 7–34.
- [3] L.A. Diaz Jr., A. Bardelli, Liquid biopsies: genotyping circulating tumor DNA, *J. Clin. Oncol.* 32 (6) (2014) 579–586.
- [4] J. Bakkum-Gamez, S. Dowdy, Retooling the pap smear for ovarian and endometrial cancer detection, *Clin. Chem.* 60 (1) (2014) 22–24.
- [5] C.P. DeSimone, et al., Rate of pathology from atypical glandular cell pap tests classified by the Bethesda 2001 nomenclature, *Obstet. Gynecol.* 107 (6) (2006) 1285–1291.
- [6] I. Kinde, et al., Evaluation of DNA from the Papanicolaou test to detect ovarian and endometrial cancers, *Sci. Transl. Med.* 5 (167) (2013) 167ra4.
- [7] Y. Wang, et al., Evaluation of liquid from the Papanicolaou test and other liquid biopsies for the detection of endometrial and ovarian cancers, *Sci. Transl. Med.* 10 (433) (2018).
- [8] I. Kinde, et al., Detection and quantification of rare mutations with massively parallel sequencing, *Proc. Natl. Acad. Sci. U. S. A.* 108 (23) (2011) 9530–9535.
- [9] J.J. Salk, et al., Enhancing the accuracy of next-generation sequencing for detecting rare and subclonal mutations, *Nat Rev Genet* 19 (5) (2018) 269–285.
- [10] S.R. Kennedy, et al., Detecting ultralow-frequency mutations by Duplex Sequencing, *Nat. Protoc.* 9 (11) (2014) 2586–2606.
- [11] M.W. Schmitt, et al., Detection of ultra-rare mutations by next-generation sequencing, *Proc. Natl. Acad. Sci. U. S. A.* 109 (36) (2012) 14508–14513.
- [12] J.D. Krimmel, et al., Ultra-deep sequencing detects ovarian cancer cells in peritoneal fluid and reveals somatic *TP53* mutations in noncancerous tissues, *Proc. Natl. Acad. Sci. U. S. A.* 113 (21) (2016) 6005–6010.
- [13] A.A. Ahmed, et al., Driver mutations in *TP53* are ubiquitous in high grade serous carcinoma of the ovary, *J. Pathol.* 221 (1) (2010) 49–56.
- [14] TCGA, Integrated genomic analyses of ovarian carcinoma, *Nature* 474 (7353) (2011) 609–615.
- [15] R. Vang, et al., Molecular alterations of *TP53* are a defining feature of ovarian high-grade serous carcinoma: a Rereview of cases lacking *TP53* mutations in the Cancer genome atlas ovarian study, *Int. J. Gynecol. Pathol.* 35 (1) (2016) 48–55.

- [16] E. Kuhn, et al., TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma—evidence supporting the clonal relationship of the two lesions, *J. Pathol.* 226 (3) (2012) 421–426.
- [17] R.A. Risques, S.R. Kennedy, Aging and the rise of somatic cancer-associated mutations in normal tissues, *PLoS Genet.* 14 (1) (2018), e1007108.
- [18] J.J. Salk, et al., Ultra-sensitive TP53 sequencing for cancer detection reveals progressive clonal selection in normal tissue over a century of human lifespan, *Cell Rep.* 28 (1) (2019) 132–144 e3.
- [19] K. Yizhak, et al., RNA sequence analysis reveals macroscopic somatic clonal expansion across normal tissues, *Science* 364 (6444) (2019).
- [20] S.R. Kennedy, et al., Cancer-associated mutations but no cancer: insights into the early steps of carcinogenesis and implications for early cancer detection, *Trends in Cancer* 5 (9) (2019) 531–540.
- [21] T. Walsh, et al., Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing, *Proc. Natl. Acad. Sci. U. S. A.* 108 (44) (2011) 18032–18037.
- [22] K.P. Pennington, et al., Germline and somatic mutations in homologous recombination genes predict platinum response and survival in ovarian, fallopian tube, and peritoneal carcinomas, *Clin. Cancer Res.* 20 (3) (2014) 764–775.
- [23] D. Nachmanson, et al., Targeted genome fragmentation with CRISPR/Cas9 enables fast and efficient enrichment of small genomic regions and ultra-accurate sequencing with low DNA input (CRISPR-DS), *Genome Res.* 28 (10) (2018) 1589–1599.
- [24] T. Tikkanen, et al., Seshat: a Web service for accurate annotation, validation, and analysis of TP53 variants generated by conventional and next-generation sequencing, *Hum. Mutat.* 39 (7) (2018) 925–933.
- [25] L.B. Alexandrov, et al., Signatures of mutational processes in human cancer, *Nature* 500 (7463) (2013) 415–421.
- [26] G. Genovese, et al., Clonal hematopoiesis and blood-cancer risk inferred from blood DNA sequence, *N. Engl. J. Med.* 371 (26) (2014) 2477–2487.
- [27] S. Jaiswal, et al., Age-related clonal hematopoiesis associated with adverse outcomes, *N. Engl. J. Med.* 371 (26) (2014) 2488–2498.
- [28] M. Xie, et al., Age-related mutations associated with clonal hematopoietic expansion and malignancies, *Nat. Med.* 20 (12) (2014) 1472–1478.
- [29] A.L. Young, et al., Clonal haematopoiesis harbouring AML-associated mutations is ubiquitous in healthy adults, *Nat. Commun.* 7 (2016), 12484.
- [30] I. Martincorena, et al., Tumor evolution. High burden and pervasive positive selection of somatic mutations in normal human skin, *Science* 348 (6237) (2015) 880–886.
- [31] I. Martincorena, et al., Somatic mutant clones colonize the human esophagus with age, *Science* 362 (6417) (2018) 911–917.
- [32] A. Yokoyama, et al., Age-related remodelling of oesophageal epithelia by mutated cancer drivers, *Nature* 565 (7739) (2019) 312–317.
- [33] M.S. Anglesio, et al., Cancer-associated mutations in endometriosis without cancer, *N Engl J Med.* 376 (19) (2017) 1835–1848.
- [34] N. Nair, et al., Genomic analysis of uterine lavage fluid detects early endometrial cancers and reveals a prevalent landscape of driver mutations in women without histopathologic evidence of cancer: a prospective cross-sectional study, *PLoS Med.* 13 (12) (2016), e1002206.
- [35] K. Suda, et al., Clonal expansion and diversification of cancer-associated mutations in endometriosis and normal endometrium, *Cell Rep.* 24 (7) (2018) 1777–1789.
- [36] R.J. Kurman, M. Shih Ie, The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory, *Am. J. Surg. Pathol.* 34 (3) (2010) 433–443.
- [37] E. Maritschnegg, et al., Lavage of the uterine cavity for molecular detection of Mullerian duct carcinomas: a proof-of-concept study, *J. Clin. Oncol.* 33 (36) (2015) 4293–4300.
- [38] K.H. Lu, Screening for ovarian cancer in asymptomatic women, *JAMA* 319 (6) (2018) 557–558.